Kleinostheim, 31 Oct. 2003 At today's Extraordinary Meeting, curasan AG's shareholders approved the sale of the company's Pharmaceuticals business unit (also referred to as "AIEP" business unit) to DeltaSelect GmbH, a subsidiary of the exchange-listed German enterprise PlasmaSelect AG. Thus, the Pharmaceuticals business unit will be transferred to Delta Select GmbH effective, in commercial terms, from 1 November 2003.

The sale mainly covers intangible rights (drug approvals, distribution rights), customer and supplier relationships, and current projects associated with the Pharmaceuticals business unit. Part of the staff will be taken over by the purchaser. The proceeds of the sale depend, to a certain extent, on the existing inventories at the date of transfer and will range between EUR 13 million and EUR 14.5 million.

The strategic alignment of curasan AG in favour of regenerative medicine, a campaign which was spearheaded in July 2000 as part of the company's IPO, has resulted in a comprehensive product portfolio. In addition, curasan has positioned itself as an international player. The additional cash resources associated with the sale are designed to accelerate market penetration on a global scale and to provide fresh impetus when it comes to rolling out products currently in the development pipeline.

Instead of the anticipated break-even result, the company now expects to achieve a net profit of around two million euros in the 2003 financial year, which corresponds to 40 cents per share.